|
|
| Industrie Pharmaceutique > Etude de marché sectorielle |
|
|
|
|
€ 3 160,00 |
Editeur
: |
Global Industry Analyst |
Langue
: |
Anglais |
Date de publication : |
Juin 2007 |
Taille du document : |
211 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
Documents Publics |
1,200,000
documents |
Téléchargement illimités |
|
|
|
Etudes Privées |
50,000 rapports et études |
Paiement à la piéce |
|
|
|
|
| |
|
1.Télécharger nos rapports publics
Accés complet à plus de 1,2 Million de documents publics : études de marché, statistiques sectorielles, fiches pays, monographie d'entreprises, veille concurentielle, rapports annuels...
|
| Nos documents publics sur le même théme (5) |
|
|
|
| 86 pages | Août 2005 | Anglais
|
|
|
| Main
focus: |
pharmaceuticals,pharmaceutical,pharmacovigilance
|
| Research
focus: |
industry structure,market size and estimates, |
| Geographic
focus: |
usa,united kingdom,india,germany,thailand,nigeria,... |
| |
|
|
|
|
| 96 pages | Juillet 2006 | Anglais
|
|
|
| Main
focus: |
pharmaceuticals,pharmaceutical,...,banks
|
| Research
focus: |
market size and estimates,market definition, |
| Geographic
focus: |
usa,china,france,canada,bermuda,israel,japan,india,... |
| |
|
|
|
|
| 64 pages | Mars 2005 | Anglais
|
|
|
| Main
focus: |
pharmaceuticals,atherosclerosis,hypertension
|
| Research
focus: |
market size and estimates,market outlook, |
| Geographic
focus: |
usa,france,canada |
| |
|
|
|
|
| 64 pages | Novembre 2005 | Anglais
|
|
|
| Main
focus: |
pharmaceuticals,dyslipidemia,pharmaceutical,...,...
|
| Research
focus: |
market size and estimates,market outlook, |
| Geographic
focus: |
usa,france,canada,poland |
| |
|
|
|
|
| 48 pages | Décembre 2006 | Anglais
|
|
|
| Main
focus: |
hospital,emergency,hospitals,medical hospital,...
|
| Research
focus: |
competition analysis,market definition, |
| Geographic
focus: |
usa,india,mexico,france,united kingdom |
| |
|
|
|
|
| Autres recherches sur le même thème |
|
|
|
| |
| |
|
| |
|
2.
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
The Drug Delivery Outlook to 2005
150 pages | Février 1999 |
Strategic overview : defines and values the market covered in the report, provides a macro analysis of the reasons why the drug delivery sector is growing at current rates and predicts how the c |
795,00 €
|
| |
| |
Top Ten and Emerging Pharmaceutical markets
214 pages | Juillet 1999 |
Introduction : Provides the background to the report by identifying the major trends within global healthcare markets and how these interact and influence the markets for pharmaceuticals.
Mar |
795,00 €
|
| |
| |
Healthcare In Northern Ireland
52 pages | Mai 2000 |
The Northern Ireland Presentation Includes:- The Structure Of The Health Service In Northern Ireland- Total Expenditure On Health & Personal Social Services- Number Of Inpatient Beds, BY Area- Occ |
327,00 €
|
| |
| |
Pharmaceutical Pricing Strategies 2000: Entering the new millennium
240 pages | Juin 2000 |
The favorable climate of the pharmaceutical sector has changed radically over the past ten years.
Where once a company's freedom over pricing decisions was almost limitless, external pressure |
955,00 €
|
| |
| |
Maximising the Drug Lifecycle
102 pages | Août 2001 |
Up to $100bn of the 2000 pharmaceutical market, including blockbuster drugs with combined sales of $34bn will be exposed to generic competition by 2005.Maximising The Drug Lifecycle provides a detaile |
955,00 €
|
| |
| |
The Pharmacogenomics Outlook
174 pages | Août 2000 |
Pharmaceutical companies are coming under increasing pressure to increase the quality of their products, and optimize and accelerate drug discovery and development.
By identifying differenc |
955,00 €
|
| |
| |
Lifestyle Drugs Outlook to 2005
130 pages | Février 1999 |
Definition of lifestyle drugs : The disease, product and social characteristics that make a drug lifestyle drug.
Epidemiology : The patient potential for lifestyle drugs such as sexual dysfuncti |
795,00 €
|
| |
| |
Pain Therapeutics: A Strategic Re-evaluation.
198 pages | Août 2000 |
Pain management, though not a life-threatening disease, will have its proper place in the future healthcare system because the disability and economic loss in addition to personal suffering caused |
955,00 €
|
| |
| |
Pharmaceutical Pricing Strategies
121 pages | Juillet 1998 |
Which pricing strategies will enable your company to maximise profitability? As healthcare cost-containment intensifies and pricing freedom is eroded, the need to develop new strategies to mainta |
795,00 €
|
| |
| |
The Pharmaceutical Industry Online
88 pages | Juillet 2002 |
In the United States, eMarketer projects that business-to-business e-commerce trade will grow to $1.3 trillion by 2005, while online trade in the health car |
800,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
|
|
This report analyzes the US market for Intranasal Drug Delivery in US$ Million. The product is analyzed by the following Therapeutic Areas: Allergic Infections, Analgesics, Osteoporosis, and Vaccinations. Annual forecasts are provided for for the period of 2000 through 2010. The report profiles 78 companies including many key and niche players such as Aegis Therapeutics LLC, Alza Corporation, AptarGroup, Inc., Archimedes Pharma, AstraZeneca Plc, Bayer Consumer Care, Bespak Plc, GlaxoSmithKline Plc, Intranasal Therapeutics, Inc., Javelin Pharmaceuticals, Inc., Kurve Technology, Inc., MedImmune, Inc., Nastech Pharmaceutical Company, Inc., Novartis AG, OptiNose AS, Pfizer, Inc., Rexam Plc, Schering-Plough Corporation, Sanofi-Aventis S.A., and Unigene Laboratories, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
|
|
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
II. A US MARKET REPORT
1. Industry Overview II-1
2. Market Dynamics II-9
3. Technology Overview II-14
4. Nasal Drugs: An Overview II-22
5. Research & Development II-31
6. Recent Technological Developments II-37
7. Product Innovations/Introductions II-39
8. Recent Industry Activity II-42
9. Focus on Select Global Players II-51
10. Market Analytics II-57
III. COMPETITION
A. Primary Players III-1
1. Alza Corporation (USA) III-1
2. AstraZeneca PLC (UK) III-4
3. Glaxosmithkline PLC (UK) III-12
4. Intranasal Therapeutics, Inc. (ITI) (USA) III-23
5. Kurve Technology, Inc. (USA) III-24
6. MedImmune, Inc. (USA) III-25
7. Nastech Pharmaceutical Company, Inc. (USA) III-31
8. Novartis AG (Switzerland) III-34
9. Pfizer, Inc. (USA) III-43
10. Schering-Plough Corporation (USA) III-47
11. Unigene Laboratories, Inc. (USA) III-56
12. Xlear, Inc. (USA) III-57
B. Niche & Other Players III-58
13. 3M Drug Delivery Systems (USA) III-58
14. Accentia Biopharmaceuticals (USA) III-59
15. Aegis Therapeutics LLC (USA) III-61
16. Alcon Laboratories, Inc. (USA) III-62
17. Amarin Corporation PLC (UK) III-64
18. AptarGroup, Inc. (USA) III-66
19. Archimedes Pharma Limited (UK) III-69
20. Armstrong Pharmaceuticals, Inc. (USA) III-70
21. Bang & Olufsen Medicom A/S (Denmark) III-71
22. Becton Dickinson and Company (USA) III-72
BD Medical Pharmaceutical Systems (USA) III-73
BD Pharmaceutical Systems (Europe) III-74
23. Bentley Pharmaceuticals, Inc. (USA) III-75
24. Bespak PLC (UK) III-76
25. Bioactis Ltd. (Japan) III-77
26. Biocon Ltd. (India) III-78
27. Biologische Heilmittel Heel GmbH (Germany) III-80
28. BioProgress PLC (UK) III-82
29. Boehringer Ingelheim GmbH (Germany) III-83
30. Cardinal Health, Inc. (USA) III-85
31. Collegium Pharmaceutical, Inc. (USA) III-88
32. DARA Biosciences, Inc. (USA) III-88
33. DelSite Biotechnologies, Inc. (USA) III-89
34. DPT Laboratories Ltd. (USA) III-90
35. Fabre-Kramer Pharmaceuticals, Inc. (USA) III-91
36. Ferring Pharmaceuticals (USA) III-92
37. First Principals, Inc. (USA) III-93
38. Generex Biotechnology Corporation (Canada) III-94
39. Gerresheimer Group GmbH (Germany) III-96
40. Ing. Erich Pfeiffer GmbH (Germany) III-97
41. Inspire Pharmaceuticals, Inc. (USA) III-98
42. Inyx, Inc. (USA) III-100
43. Javelin Pharmaceuticals, Inc. (USA) III-103
44. Lee Pharmaceuticals (USA) III-104
45. Les Laboratoires Servier (France) III-106
46. Lyfjathroun Biopharmaceuticals Ltd. (Iceland) III-107
47. MAP Pharmaceuticals, Inc. (USA) III-108
48. MatTek Corporation (USA) III-109
49. MedPharm Ltd. (UK) III-109
50. Merck & Co., Inc. (USA) III-110
51. Morton Grove Pharmaceuticals, Inc. (USA) III-112
52. NasVax Ltd. (Israel) III-112
53. Next Breath LLC (USA) III-113
54. Nycomed (Denmark) III-114
55. OptiNose AS (Norway) III-116
56. Organon International, Inc. (USA) III-116
57. Palatin Technologies, Inc. (USA) III-117
58. Par Pharmaceutical Companies, Inc. (USA) III-119
59. Pari Respiratory Equipment, Inc. (USA) III-121
60. Pharmaceutical Profiles Group (UK) III-122
61. Pherin Pharmaceuticals, Inc. (USA) III-123
62. Procter & Gamble Pharmaceuticals (USA) III-124
63. Ranbaxy Laboratories Ltd. (India) III-125
64. Reckitt Benckiser Healthcare (UK) III-127
65. Rexam PLC (UK) III-128
66. Sanofi-Aventis (France) III-130
67. Schott Forma Vitrum (USA) III-134
68. Shin Nippon Biomedical Laboratories (Japan) III-135
69. SiCap Industries LLC (USA) III-137
70. SinoFresh HealthCare, Inc. (USA) III-138
71. Skyepharma PLC (UK) III-139
72. Taro Pharmaceuticals Ltd. (UK) III-140
73. Teva Pharmaceutical Industries Ltd. (Israel) III-141
74. Tzamal Bio Pharma Ltd. (Israel) III-143
75. Upsher-Smith Laboratories, Inc. (USA) III-144
76. Ursatec Packing GmbH/Ursatec Verpackung-GmbH (Germany) III-145
77. Wolfe Tory Medical, Inc. (USA) III-145
78. Xemplar Pharmaceuticals LLC (USA) III-146
|
|
|
PPLSEN
|
|
|
|
|
